Companies Will Discuss Recent FDA Advisory Regarding BYETTA
SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) will Web cast a
conference call on Tuesday, August 26 at 5:00 p.m. ET/2:00 p.m. PT to
discuss the recent FDA advisory on BYETTA(R) (exenatide) injection. Leading
the call for Amylin will be Daniel M. Bradbury, Amylin's President and
Chief Executive Officer and Orville G. Kolterman, M.D., Amylin's Senior
Vice President of Research and Development. Leading the call for Lilly will
be Donald Therasse, M.D., Lilly's Vice President of Global Patient Safety.
The call will be Web cast live through Amylin's corporate Web site and
a recording will be made available following the close of the call. To
access the Web cast, please log on to http://www.amylin.com approximately
fifteen minutes prior to the call to register, download and install any
necessary audio software. For those without access to the Internet, the
live call may be accessed by phone by calling (866) 814-1915 (domestic) or
(703) 639-1359 (international), passcode 1277182. A replay of the call will
also be available by phone through September 26, 2008 beginning
approximately one hour after the close of the call and can be accessed at
(888) 266-2081 (domestic) or (703) 925-2533 (international), passcode
1277182.
About Amylin and Lilly
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California with over 2,000 employees
nationwide. Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
Through a long-standing commitment to diabetes care, Lilly provides
patients with breakthrough treatments that enable them to live longer,
healthier and fuller lives. Since 1923, Lilly has been the industry leader
in pioneering therapies to help health care professionals improve the lives
of people with diabetes, and research continues on innovative medicines to
address the unmet needs of patients. For more information about Lilly's
current diabetes products visit http://www.lillydiabetes.com.
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Indiana, Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs.
Additional information about Lilly is available at http://www.lilly.com.
SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
 back to top
Related links:
http://www.amylin.com
http://www.lilly.com
CONTACT:
Michael York, Senior Director, Investor
Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, x8602
|
